Prosecution Insights
Prosecution Insights
44 pending office actions • 16 clients • 44 examiners • 34 art units • 0 of 44 (0%) have an AI response strategy ready • 49 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 44 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 44 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §103 only | 32 (73%) |
| §102 only | 5 (11%) |
| §112 only | 1 (2%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 2 (5%) |
| No statute on record | 2 (5%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TAWFIK, SAMEH | 1 | 63.0% | +30.9% |
| ANGELL, JON E | 1 | 70.7% | +21.1% |
| QI, ZHENGQING J | 1 | 68.8% | +13.8% |
| DEHGHAN, QUEENIE S | 1 | 61.8% | +10.9% |
| KRUSE, DAVID H | 1 | 81.7% | +8.9% |
| SAMSELL, RILLA MARIE | 1 | 71.4% | +0.0% |
| SAEED, ALI S | 1 | 30.5% | +34.8% |
| ULLMAN, AARON RAFANAN | 1 | — | — |
| CASH, KAILEY ELIZABETH | 1 | 28.6% | +48.9% |
| GU, QINHUA | 1 | 75.0% | +30.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18290679 | PTPRS IN AUTOIMMUNITY | KRUSE, DAVID H | 28d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638428 | GENE FRAGMENT OVEREXPRESSION SCREENING METHODOLOGIES, AND USES THEREOF | HELLMAN, KRISTINA M | 33d |
| 18285222 | BLOCKING OLIGONUCLEOTIDES FOR THE SELECTIVE DEPLETION OF NON-DESIRABLE FRAGMENTS FROM AMPLIFIED LIBRARIES | CASH, KAILEY ELIZABETH | 70d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19084155 | FOLDING RAIL | TAWFIK, SAMEH | 44d overdue |
| 18664227 | LIDAR SYSTEM GENERATING MULTIPLE LIDAR OUTPUT SIGNALS | QI, ZHENGQING J | 16d overdue |
| 18636709 | SILICON MOLD FOR HIGH TEMPERATURE COMPRESSION MOLDING AND PREPARATION METHOD THEREOF | DEHGHAN, QUEENIE S | 9d |
| 18786394 | RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES | ANGELL, JON E | 30d |
| 18285000 | MODIFIED VIRUSES AND VIRAL PARTICLES, METHODS OF MAKING, AND USES THEREOF | GU, QINHUA | 42d |
| 18285222 | BLOCKING OLIGONUCLEOTIDES FOR THE SELECTIVE DEPLETION OF NON-DESIRABLE FRAGMENTS FROM AMPLIFIED LIBRARIES | CASH, KAILEY ELIZABETH | 70d |
| 18572637 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | SAEED, ALI S | 76d |
| Art Unit | Apps |
|---|---|
| 3645 | 5 |
| 1628 | 3 |
| 1633 | 2 |
| 1654 | 2 |
| 1638 | 2 |
| 1653 | 2 |
| 3731 | 1 |
| 1637 | 1 |
| 1741 | 1 |
| 1663 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19084155 | FOLDING RAIL | Origin Materials Operating, Inc. | TAWFIK, SAMEH | 3731 | §102 | Non-Final OA | 44d overdue | Pending | Mar 19, 2025 |
| 18786394 | RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES | The Regents of the University of California | ANGELL, JON E | 1637 | §102 | Non-Final OA | 30d | Pending | Jul 26, 2024 |
| 18664227 | LIDAR SYSTEM GENERATING MULTIPLE LIDAR OUTPUT SIGNALS | Silc Technologies, Inc. | QI, ZHENGQING J | 3645 | §103 | Non-Final OA | 16d overdue | Pending | May 14, 2024 |
| 18636709 | SILICON MOLD FOR HIGH TEMPERATURE COMPRESSION MOLDING AND PREPARATION METHOD THEREOF | Huatong Optical Technology (Zhejiang) Co., Ltd. | DEHGHAN, QUEENIE S | 1741 | §103 | Non-Final OA | 9d | Pending | Apr 16, 2024 |
| 18290679 | PTPRS IN AUTOIMMUNITY | The Regents of the University of California | KRUSE, DAVID H | 1663 | §102 | Non-Final OA | 28d overdue | Pending | Jan 19, 2024 |
| 18573359 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | Ldn Pharma Limited | SAMSELL, RILLA MARIE | 1624 | Other | Non-Final OA | 20d | Pending | Dec 21, 2023 |
| 18572637 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | Ldn Pharma Limited | SAEED, ALI S | 1616 | DPOther | Non-Final OA | 76d | Pending | Dec 20, 2023 |
| 18572651 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | Ldn Pharma Limited | ULLMAN, AARON RAFANAN | 1628 | §103 | Non-Final OA | 83d | Pending | Dec 20, 2023 |
| 18285222 | BLOCKING OLIGONUCLEOTIDES FOR THE SELECTIVE DEPLETION OF NON-DESIRABLE FRAGMENTS FROM AMPLIFIED LIBRARIES | Illumina, Inc. | CASH, KAILEY ELIZABETH | 1683 | §103 | Non-Final OA | 70d | Pending | Sep 29, 2023 |
| 18285000 | MODIFIED VIRUSES AND VIRAL PARTICLES, METHODS OF MAKING, AND USES THEREOF | The Regents of the University of California | GU, QINHUA | 1633 | §103 | Non-Final OA | 42d | Pending | Sep 29, 2023 |
| 18280093 | USE OF MESENCHYMAL STEM CELLS OVEREXPRESSING PACER FOR THE TREATMENT OF DISEASES WITH INFLAMMATORY ORIGIN AND/OR COMPONENT | Universidad del Desarrollo | RAHMAN, MASUDUR | 1633 | §103 | Non-Final OA | 39d | Pending | Sep 01, 2023 |
| 18231114 | AUTOIMMUNE THERAPY | Ldn Pharma Limited | COPPINS, JANET L | 1628 | §103 | Final Rejection | 83d | Pending | Aug 07, 2023 |
| 18226739 | DEVICES AND METHODS FOR CONTINUOUS DIELECTROPHORESIS CELL SORTING TO ISOLATE DIFFERENT POPULATIONS OF CELLS, AND APPLICATIONS THEREOF | The Regents of the University of California | LYLE, SOPHIA YUAN | 1796 | §103 | Non-Final OA | 65d | Pending | Jul 26, 2023 |
| 18273710 | NALTREXONE COMPOSITIONS | Ldn Pharma Limited | ARNOLD, ERNST V | 1613 | §103 | Final Rejection | 49d overdue | Pending | Jul 21, 2023 |
| 18273491 | THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF CDKL5 GENE | The Regents of the University of California | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §103 | Non-Final OA | 14d | Pending | Jul 20, 2023 |
| 18271829 | INHIBITOR FOR CHRONIC MYELOID LEUKEMIA STEM CELLS | Saga University | CRAIGO, BAHAR ALAWI | 1699 | §103 | Non-Final OA | 23d | Pending | Jul 11, 2023 |
| 17924554 | COMPOSITION COMPRISING PEPTIDE, AND USE THEREOF | Kola-Gen Pharma Inc. | BOWLES, DAVID PAUL | 1654 | DP | Non-Final OA | 83d | Pending | Jun 12, 2023 |
| 18330163 | ASSAY TO IDENTIFY ANTI-CANCER AGENTS | Ldn Pharma Limited | HOWELL, THEODORE R | 1628 | DPOther | Non-Final OA | 69d | Pending | Jun 06, 2023 |
| 18297593 | RECOMBINANTLY ENGINEERED POLYPEPTIDES CAPABLE OF RECYCLING NONCANONICAL COFACTORS | The Regents of the University of California | LEE, JIA-HAI | 1658 | §102 | Non-Final OA | 26d | Pending | Apr 07, 2023 |
| 18028740 | COMPOSITION AND METHODS FOR MODULATING TCF4 GENE EXPESSION AND TREATING PITT HOPKINS SYNDROME | The Regents of the University of California | THUESON, HANNA MARIE | 1638 | §103 | Non-Final OA | 86d | Pending | Mar 27, 2023 |
| 18026287 | HYBRID PROTOCOLS AND BARCODING SCHEMES FOR MULTIPLE SEQUENCING TECHNOLOGIES | The Regents of the University of California | DAUNER, JOSEPH G | 1682 | §103 | Non-Final OA | 35d overdue | Pending | Mar 14, 2023 |
| 18119274 | DATA RESOLUTION IN LIDAR SYSTEMS | Silc Technologies, Inc. | HELLNER, MARK | 3645 | §112 | Non-Final OA | 30d overdue | Pending | Mar 08, 2023 |
| 18106995 | DATA REFINEMENT IN OPTICAL SYSTEMS | Silc Technologies, Inc. | HUTCHENS, CHRISTOPHER D. | 3647 | §103 | Non-Final OA | 29d overdue | Pending | Feb 07, 2023 |
| 18104770 | SCANNING MULTIPLE LIDAR SYSTEM OUTPUT SIGNALS | Silc Technologies, Inc. | THATCHER, CLINT A | 3645 | §103 | Non-Final OA | 60d overdue | Pending | Feb 01, 2023 |
| 18006011 | GUN SHOT RESIDUE FIELD KIT | VERITEQUE USA, INC. | FRITCHMAN, REBECCA M | 1758 | §103 | Non-Final OA | 16d overdue | Pending | Jan 19, 2023 |
| 18097261 | OPTICAL BRIDGES FOR PHOTONIC INTEGRATED CIRCUITS | Silc Technologies, Inc. | TAVLYKAEV, ROBERT FUATOVICH | 2896 | §103 | Final Rejection | 30d overdue | Pending | Jan 15, 2023 |
| 18076001 | ANTI-AGING DERMATOLOGICAL COMPOSITIONS | Dr. Sabrina Ltd. | WRIGHT, SARAH C | 1619 | §103 | Non-Final OA | 7d | Pending | Dec 06, 2022 |
| 18072666 | CONTROL OF SIGNAL CHIRP IN LIDAR SYSTEMS | Silc Technologies, Inc. | CHILTON, CLARA GRACE | 3645 | §103 | Non-Final OA | 50d overdue | Pending | Nov 30, 2022 |
| 18048386 | THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS | The Regents of the University of California | SZPERKA, MICHAEL EDWARD | 1641 | §102 | Final Rejection | 26d | Pending | Oct 20, 2022 |
| 17914274 | ANTI-ACINETOBACTER BAUMANNII POLYCLONAL ANTIBODY (AB-pAb), AND USES THEREOF | The Regents of the University of California | ZEMAN, ROBERT A | 1645 | §103 | Final Rejection | 92d overdue | Pending | Sep 23, 2022 |
| 17945072 | COMBINING DATA FROM DIFFERENT SAMPLE REGIONS IN AN IMAGING SYSTEM FIELD OF VIEW | Silc Technologies, Inc. | HULKA, JAMES R | 3645 | §103 | Non-Final OA | 3d overdue | Pending | Sep 14, 2022 |
| 17786913 | BIOSYNTHETIC PLATFORM FOR THE PRODUCTION OF CANNABINOIDS AND OTHER PRENYLATED COMPOUNDS | The Regents of the University of California | RAMIREZ, DELIA M | 1652 | Other | Final Rejection | 43d overdue | Pending | Jun 17, 2022 |
| 17781345 | DEVICE AND METHOD FOR DETECTING A SURFACE SHAPE ON THE HUMAN OR ANIMAL BODY | Bellwald Tec GmbH - Nws | ASGHAR, AMINAH | 3797 | §103 | Non-Final OA | 88d overdue | Pending | May 31, 2022 |
| 17781173 | NEW USE OF REGEND001 CELL AUTOLOGOUS DELIVERABLE PREPARATION IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | Regend Therapeutics Co., Ltd. | TICHY, JENNIFER M.H. | 1653 | §103 | Final Rejection | 59d overdue | Pending | May 31, 2022 |
| 17775217 | BIOMARKER OF DRUG-INDUCED CELLULAR TOXICITY AND DEPRESSION | Randox Laboratories Ltd. | WESTERBERG, NISSA M | 1618 | §103 | Non-Final OA | 9d | Pending | May 06, 2022 |
| 17638428 | GENE FRAGMENT OVEREXPRESSION SCREENING METHODOLOGIES, AND USES THEREOF | The Regents of the University of California | HELLMAN, KRISTINA M | 1654 | §101 | Non-Final OA | 33d | Pending | Feb 25, 2022 |
| 17584129 | METHODS AND THERAPIES FOR TREATING ATHEROSCLEROSIS AND/OR HYPERLIPIDEMIA USING OLIGOSACCHARIDES | The Regents of the University of California | OLSON, ANDREA STEFFEL | 1693 | §103 | Non-Final OA | 35d | Pending | Jan 25, 2022 |
| 17625442 | SPECIFIC MARKER FOR IDENTIFYING T CELLS SPECIFICALLY ATTACKING CANCER CELLS | Kotai Biotechnologies, Inc. | MCCORMICK, CATHERINE LYNN | 1638 | §103 | Non-Final OA | 59d overdue | Pending | Jan 07, 2022 |
| 17617278 | BIOCIDAL COMPOSITE MATERIAL | Pennog Limited | TRUONG, QUANGLONG N | 1615 | §103 | Non-Final OA | 84d | Pending | Dec 07, 2021 |
| 17437724 | CANCER TREATMENT COMPRISING NALTREXONE AND A CANNABINOID | Ldn Pharma Limited | MAHLUM, JONATHAN DAVIS | 1625 | §103 | Final Rejection | 34d | Pending | Sep 09, 2021 |
| 17435911 | METHOD FOR DETERMINING EFFICACY | Ldn Pharma Limited | MOSS, NATALIE M | 1653 | §103 | Final Rejection | 8d overdue | Pending | Sep 02, 2021 |
| 17294358 | DETECTION OF BLADDER CANCER | Randox Laboratories Ltd. | MONTGOMERY, ANN Y | 1678 | §103 | Final Rejection | 28d | Pending | May 14, 2021 |
| 17049320 | SPIKED PRIMERS FOR ENRICHMENT OF PATHOGEN NUCLEIC ACIDS AMONG BACKGROUND OF NUCLEIC ACIDS | The Regents of the University of California | RYAN, DOUGLAS CHARLES | 1635 | §103 | Non-Final OA | 9d | Pending | Oct 20, 2020 |
| 16776405 | PATHOGEN DETECTION USING NEXT GENERATION SEQUENCING | The Regents of the University of California | DHARITHREESAN, NIDHI | 1686 | §103 | Final Rejection | 33d | Pending | Jan 29, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial